April 8, 2024
CellCarta’s study utilizes tumor RNA-sequencing data to predict immune checkpoint inhibition (ICI) response in cancer patients. The developed RNA-Seq Bio-IT model integrates features like tumor mutational burden (TMB), microsatellite instability (MSI), tumor infiltrating lymphocytes (TILs), and immune gene expression signatures to enhance the prediction of clinical responses to ICI therapy.
This model reduces the complexity and cost associated with multi-omics approaches and provides a more accurate prediction of therapy outcomes, potentially improving patient selection for ICI treatment.
View the poster:
Exploiting tumor RNA-sequencing data for prediction of immune checkpoint inhibition response
Posters
June 23, 2025
More infoPosters
June 23, 2025
More infoCellTalk Blog
June 10, 2025
More infoCellTalk Blog
June 4, 2025
More info